

E.2 Antidepressants (duloxetine, fluoxetine, moclobemide) versus placebo

Figure 21: Quality of life: SF-36 subscales at 12 weeks (duloxetine)




Figure 22: Fatigue: 14-item Chalder fatigue scale at 26 weeks (fluoxetine)




Figure 23: Fatigue: MFI-20 at 12 weeks (duloxetine)




Figure 24: Fatigue: Checklist Individual Strength (CIS) fatigue at 16 weeks (fluoxetine)




Figure 25: Physical functioning: Karnofsky Performance Index at 6 weeks (moclobemide)





Figure 26: Psychological status: Profile of mood states (POMS) at 6 weeks (moclobemide)



Footnotes

(1) Vigour subscale inverted for analysis

Figure 27: Psychological status: HADS depression at 12-26 weeks (change scores) (fluoxetine or duloxetine)




Figure 28: Psychological status: HADS anxiety at 12 weeks (duloxetine)




Figure 29: Psychological status: Beck Depression Inventory at 16 weeks (fluoxetine)




Figure 30: Pain: Brief Pain Inventory at 12 weeks (duloxetine)




Figure 31: Adverse events (fluoxetine)




Figure 32: Exercise performance measure: VO2 max (mL O2/kg/min) at 26 weeks (fluoxetine)




Figure 33: Symptom scales: Clinical Global Impression at 12 weeks (duloxetine)




Figure 34: Symptom scales: CDC symptom inventory at 12 weeks (duloxetine)




Figure 35: Symptom scales: Improvement of symptoms (patient-reported) at 6-14 weeks (fluoxetine or moclobemide)




Figure 36: Symptom scales: Worsening of symptoms (patient-reported) at 14 weeks (fluoxetine)

